Last reviewed · How we verify
DiphenhydrAMINE Injectable Solution
At a glance
| Generic name | DiphenhydrAMINE Injectable Solution |
|---|---|
| Sponsor | Dent Neuroscience Research Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (PHASE1)
- A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (PHASE3)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) (PHASE2)
- Central Nervous System Effects Following Infusion of Diphenhydramine Using Pharmacokinetic and Pharmacodynamic Modeling (PHASE4)
- V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency (PHASE3)
- Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |